OnCo
drugsProductApproved2026

ArteraAI Breast

An FDA-cleared AI test (May 2026) that reads breast cancer slides to estimate recurrence risk in early hormone-positive disease.

First FDA-cleared digital-pathology-based risk stratification tool for early-stage HR+/HER2- invasive breast cancer, positioned as a faster, cheaper alternative to gene-expression assays.

Schematic of the modality · AI digital pathology risk test · not a molecule; see the Digital pathology & AI page
Mechanism, step by step
auto-advancing · hover to pause

1.H&E whole-slide images are scanned

Modality
AI digital pathology risk test
Mechanism
Foundation-model-derived features from H&E whole-slide images.
Medicare
Unknown

Newer test; no Medicare coverage determination had been published at the time of writing. Check the MolDX programme for a current decision.

Commercial insurance
unknown

Commercial coverage not yet established.

Sources: CMS Medicare Coverage Database (NCDs and LCDs) · CMS Medicare Coverage Database (NCDs and LCDs). Not medical or financial advice; verify with your plan.

Not appraisedSearch NICE
Notes
Not available on the NHS; NICE has assessed AI prognostic tools via early value assessments, not TAs.
NHS England
Not routinely funded

Sources: NICE search: ArteraAI Breast. Funding decisions are indication-specific and change monthly; verify with NICE and your treating team.

Regulatory

1top
  1. May 2026ApprovalUS

    FDA clearance: first digital-pathology-based risk stratification tool for early HR+/HER2- breast cancer source

Approvals

RegionYearIndication
US2026Risk stratification in early-stage HR+/HER2- invasive breast cancer

Cost & access

1top
Cost & access
CountryReimbursement
United StatesLaunched May 2026; coverage determinations pending

List prices are manufacturer or Medicare figures where publicly disclosed; net prices after rebates are usually lower. Reimbursement changes; check the payer.

Trials

top

Recruiting now (live from ClinicalTrials.gov)

Recruiting trials near you · live from ClinicalTrials.gov
ArteraAI Breast
intervention: ArteraAI Breast
Open on ClinicalTrials.gov →

Country and place are remembered in this browser only. A postcode is sent to OpenStreetMap's Nominatim service to find coordinates when you press the button; nothing else leaves your device.

Latest papers

top
Latest papers · live from Europe PMC
Open in Europe PMC

Query for this drug: (TITLE:"ArteraAI Breast" OR ABSTRACT:"ArteraAI Breast") AND (cancer OR tumor OR tumour OR oncology OR carcinoma OR lymphoma OR leukemia OR leukaemia OR myeloma OR sarcoma OR melanoma OR glioma). Results are unfiltered search hits about ArteraAI Breast, not a curated reading list.

Connected

7top